[{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Masupirdine","moa":"5-HT6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Suven Life Sciences Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Not Applicable"},{"orgOrder":0,"company":"MedRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Memantine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"MedRx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"MedRx \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MedRx \/ Not Applicable"},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Donepezil","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Masupirdine","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Memantine HCl

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : SUVN-502 (masupirdine) is a novel, potent, pure, and orally active 5-HT6 receptor antagonist, it is being investigated as a potential therapy against alzheimer's disease.

Brand Name : SUVN-502

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 11, 2023

Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride

Therapeutic Area : Neurology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : Cognic (donepezil) is a transactive response DNA binding protein of 43 kDa (TDP-43) is involved in regulation of gene expression. AD patients with TDP-43 pathology have increased severity of cognitive impairment compared to those without TDP-43 pathology...

Brand Name : Cognic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

January 19, 2023

Lead Product(s) : Donepezil,Memantine Hydrochloride

Therapeutic Area : Neurology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : Medrx filled an INDA with the USFDA for MRX-7MLL, a patch that uses NCTS an exclusive transdermal absorption technology contains memantine for the treatment of Alzheimers, It is shown to be bioequivalent to the oral drug containing memantine.

Brand Name : MRX-7MLL

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 10, 2021

Lead Product(s) : Memantine Hydrochloride

Therapeutic Area : Neurology

Highest Development Status : IND Enabling

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : SUVN-502 (Masupirdine), a lead clinical candidate having undergone phase 2 study on 564 patients for moderate Alzheimer’s disease without meeting primary end point.

Brand Name : SUVN-502

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 16, 2021

Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride

Therapeutic Area : Neurology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank